Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis: A Randomized Phase III Trial

In this Phase III study, JAK inhibitor-naive patients with myelofibrosis were randomized 1:1 to pelabresib 125 mg once daily for 14 days followed by a 7-day break, or to placebo in combination with ruxolitinib 10 or 15 mg twice daily.